Total Number of Communication Reports: 2
Monthly communication reports in the last 6 months: 0
End date of the last completed financial year: 2023-07-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Canada Revenue Agency (CRA) | $95,900.00 | Yes |
Scientific Research and Experimental Development – Quebec | $178,122.00 | Yes |
Address:
100-5485 Rue Pare
Montreal, QC H4P 1P7
Canada
Telephone number:
888-686-4239
Web address:
https://www.ibex.ca/
Paul Baehr, President and CEO
IBEX Pharmaceuticals Inc. / IBEX Pharmaceuticals Inc. is not a subsidiary of any other parent companies.
IBEX Pharmaceuticals Inc. / IBEX Pharmaceuticals Inc. is not a coalition.
The activities of IBEX Pharmaceuticals Inc. / IBEX Pharmaceuticals Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
IBEX Pharmaceuticals Inc. / IBEX Pharmaceuticals Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Jon Dugal | Public offices held
Firm: Syntax Strategic / Syntax Strategic